Clinical Trials Logo

Malignant Disease clinical trials

View clinical trials related to Malignant Disease.

Filter by:
  • None
  • Page 1

NCT ID: NCT05437328 Recruiting - Malignant Disease Clinical Trials

GD2/CD56 Bi-specific CAR-T Cell Therapy

Start date: June 30, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of anti-GD2/CD56 bi-specific CAR-T cell therapy in patients with GD2 and/or CD56 positive cancer. Another goal of the study is to learn more about the function of the anti-GD2/CD56 bi-specific CAR-T cells and their persistency in patients.

NCT ID: NCT03995927 Terminated - Metastasis Clinical Trials

Palliative Radiation Oncology Chief's Clinic

PROCC
Start date: July 15, 2019
Phase:
Study type: Observational

The proposed study represents a quality improvement study of a recently-developed dedicated radiation oncology subspecialty clinic with the goal of improving timeliness of palliative radiation therapy and improving resident training in palliative care topics. The aim of this study is to evaluate the impact of this clinic on time to palliative radiation therapy following referral.

NCT ID: NCT03580109 Recruiting - Breast Cancer Clinical Trials

Spa Therapy for Upper or Lower Limb Lymphoedema

THERMOEDEME
Start date: June 20, 2019
Phase: N/A
Study type: Interventional

THERMOEDEME is a comparative, controlled, randomized, multicenter and simple blinded (investigator) trial. The aim of this study is to evaluate effects of spa therapy in phlebology with a therapeutic education program in daily life of patients suffering lymphoedema.

NCT ID: NCT03560882 Active, not recruiting - Cancer Clinical Trials

A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies

Start date: July 19, 2018
Phase: Phase 1
Study type: Interventional

This is a window-of-opportunity trial to determine if atorvastatin given for 1 to 4 weeks at a dose of 80 milligrams per day (mg/day) is sufficient to decrease the level of conformational mutant tumor protein 53 (p53) in malignant diseases (solid tumor and relapsed Acute Myeloid Leukemia (AML)).

NCT ID: NCT02447237 Completed - Clinical trials for Delayed Gastric Emptying

Randomized Trial:the Effect of Liquid Food on the Intake of Energy and Protein in Malignant Hematologic Patients

Start date: March 2015
Phase: N/A
Study type: Interventional

The study investigates the effect of liquid food on the intake of energy and protein compared to solid food. One group will receive dietary counselling in fulfilling their need for energy and protein from liquid food and the other group from solid food.

NCT ID: NCT02014506 Recruiting - Malignant Disease Clinical Trials

Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation in Children and Adolescents

Start date: January 2017
Phase: Phase 1/Phase 2
Study type: Interventional

Purpose of study: This phase I/II trial is to evaluate the safety and feasibility of TCRαβ-depleted graft from haploidentical family donors in treating children and adolescents with malignant or non-malignant diseases.

NCT ID: NCT00881166 Completed - Malignant Disease Clinical Trials

Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors

SGI-0470-02
Start date: November 2007
Phase: Phase 1
Study type: Interventional

Adult subjects with malignant disease appropriate for treatment with carboplatin/paclitaxel, carboplatin/etoposide, topotecan, docetaxel or erlotinib according to the standard dosing regimen will be enrolled in each treatment arm. Primary objective: Determine the MTD. Secondary objectives: Response rates, PK, quantify MP-470 on PK of SOC, and collect pharmacodynamic information. Evaluate the overall safety of MP-470 when co-administered with specific SOC treatments.